Literature DB >> 10764669

Rapid restoration of normal endothelial functions in genetically hyperlipidemic mice by a synthetic mediator of reverse lipid transport.

K J Williams1, R Scalia, K D Mazany, W V Rodrigueza, A M Lefer.   

Abstract

Endothelial dysfunction is a major pathophysiological consequence of hypercholesterolemia and other conditions. We examined whether a synthetic mediator of lipid transport from peripheral tissues to the liver (ie, the "reverse" pathway) could restore normal endothelial function in vivo. Using assays of macrovascular and microvascular function, we found that genetically hypercholesterolemic apolipoprotein E knockout mice exhibited key endothelial impairments. Treatment of the mice for 1 week with daily intravenous bolus injections of large "empty" phospholipid vesicles, which accelerate the reverse pathway in vivo, restored endothelium-dependent relaxation, leukocyte adherence, and endothelial expression of vascular cell adhesion molecule-1 to normal or nearly normal levels. These changes occurred despite the long-standing hyperlipidemia of the animals and the persistence of high serum concentrations of cholesterol-rich atherogenic lipoproteins during the treatment. Our results indicate that dysfunctional macrovascular and microvascular endothelium in apolipoprotein E knockout mice can recover relatively quickly in vivo and that accelerated reverse lipid transport may be a useful therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764669     DOI: 10.1161/01.atv.20.4.1033

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  14 in total

Review 1.  Lipids and endothelium-dependent vasodilation--a review.

Authors:  Lars Lind
Journal:  Lipids       Date:  2002-01       Impact factor: 1.880

2.  Enhanced endothelium-dependent vasodilation in Fabry disease.

Authors:  G Altarescu; D F Moore; R Pursley; U Campia; S Goldstein; M Bryant; J A Panza; R Schiffmann
Journal:  Stroke       Date:  2001-07       Impact factor: 7.914

Review 3.  Perspectives and opportunities for nanomedicine in the management of atherosclerosis.

Authors:  Mark E Lobatto; Valentin Fuster; Zahi A Fayad; Willem J M Mulder
Journal:  Nat Rev Drug Discov       Date:  2011-10-21       Impact factor: 84.694

Review 4.  Regression of atherosclerosis: insights from animal and clinical studies.

Authors:  Jonathan E Feig
Journal:  Ann Glob Health       Date:  2013-12-25       Impact factor: 2.462

5.  Cholesterol-induced membrane microvesicles as novel carriers of damage-associated molecular patterns: mechanisms of formation, action, and detoxification.

Authors:  Ming-Lin Liu; Rosario Scalia; Jawahar L Mehta; Kevin Jon Williams
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-07-19       Impact factor: 8.311

Review 6.  The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications.

Authors:  Jonathan E Feig; Jessica L Feig; George D Dangas
Journal:  Coron Artery Dis       Date:  2016-11       Impact factor: 1.439

Review 7.  Microvesicles: potential markers and mediators of endothelial dysfunction.

Authors:  Ming-Lin Liu; Kevin Jon Williams
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-04       Impact factor: 3.243

8.  Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells.

Authors:  Mary Yk Lee; Huiying Li; Yang Xiao; Zhiguang Zhou; Aimin Xu; Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

9.  Liposomal inhibition of acrolein-induced injury in rat cultured urothelial cells.

Authors:  J Nirmal; A S Wolf-Johnston; M B Chancellor; P Tyagi; M Anthony; J Kaufman; L A Birder
Journal:  Int Urol Nephrol       Date:  2014-05-30       Impact factor: 2.370

10.  Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production.

Authors:  Meihui Pan; Arthur I Cederbaum; Yuan-Li Zhang; Henry N Ginsberg; Kevin Jon Williams; Edward A Fisher
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.